333
Views
18
CrossRef citations to date
0
Altmetric
Case Report

Dyskinesias associated with atomoxetine in combination with other psychoactive drugs

, M.D., , M.D. & , M.S. , M.D.
Pages 182-185 | Received 15 Jul 2005, Accepted 27 Sep 2005, Published online: 07 Oct 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron & Daniel Geller. (2009) Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatric Disease and Treatment 5, pages 215-226.
Read now

Articles from other publishers (17)

Fumika Sato, Akihito Suzuki, Keisuke Noto, Toshinori Shirata, Muneaki Kanno, Ryota Kobayashi & Koichi Otani. (2022) Serotonin syndrome induced by overdose of atomoxetine alone in a patient with attention‐deficit hyperactivity disorder: A case report. Psychiatry and Clinical Neurosciences Reports 1:3.
Crossref
Harvey S. Singer, Jonathan W. Mink, Donald L. Gilbert & Joseph Jankovic. 2022. Movement Disorders in Childhood. Movement Disorders in Childhood 637 666 .
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs 738 740 .
Harvey S. Singer, Jonathan W. Mink, Donald L. Gilbert & Joseph Jankovic. 2016. Movement Disorders in Childhood. Movement Disorders in Childhood 491 513 .
Jessica M. Hawthorne & Charles F. Caley. (2015) Extrapyramidal Reactions Associated With Serotonergic Antidepressants. Annals of Pharmacotherapy 49:10, pages 1136-1152.
Crossref
Arnab BhattacharyaSamir Kumar PraharajVinod Kumar Sinha. (2014) Persistent Camptocormia Associated with Atomoxetine in a Child with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology 24:10, pages 596-597.
Crossref
Henry A. Spiller, Hannah L. Hays & Alfred AleguasJr.Jr.. (2013) Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. CNS Drugs 27:7, pages 531-543.
Crossref
Tamás TreuerSusan Shur-Fen GauLuis MéndezWilliam MontgomeryJulie A. MonkMurat AltinShenghu WuChaucer C.H. LinHéctor J. Dueñas. (2013) A Systematic Review of Combination Therapy with Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder, Including Patient Characteristics, Treatment Strategies, Effectiveness, and Tolerability. Journal of Child and Adolescent Psychopharmacology 23:3, pages 179-193.
Crossref
Irina Piatkov, Trudi Jones & Mark McLean. (2012) Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics. Journal of Personalized Medicine 2:4, pages 149-157.
Crossref
Michael R. KohnTracey W. TsangSimon D. Clarke. (2012) Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder. Clinical Medicine Insights: Pediatrics 6, pages CMPed.S7868.
Crossref
Irina Piatkov, Trudi Jones & Rainei J. Van Vuuren. (2014) Suicide cases and venlafaxine. Acta Neuropsychiatrica 23:4, pages 156-160.
Crossref
Panagiotis Ferentinos, Christos Christodoulou, Emmanouil Rizos, Athanassios Douzenis & Lefteris Lykouras. (2010) Mixed-Type (Limb-Truncal and Orofacial) Bupropion-Associated Dyskinesia. Journal of Clinical Psychopharmacology 30:5, pages 644-646.
Crossref
Reginald P. Sequeira. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions 1 28 .
Harvey S. Singer, Jonathan W. Mink, Donald L. Gilbert & Joseph Jankovic. 2010. Movement Disorders in Childhood. Movement Disorders in Childhood 231 241 .
Donald L. Gilbert. (2008) Drug-induced Movement Disorders in Children. Annals of the New York Academy of Sciences 1142:1, pages 72-84.
Crossref
. (2007) Prescriptions Into Practice. Child and Adolescent Psychopharmacology News 12:5, pages 4-10.
Crossref
. (2007) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 16:10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.